Specialty Pharmacy

FLINT, Mich. — Diplomat Pharmacy on Thursday announced the planned acquisition of Valley Campus Pharmacy, which does business as TNH Advanced Specialty Pharmacy (TNH). The deal will see the nation’s largest independent specialty pharmacy acquiring the seven-year-old oncology-focused company for $75 million, a mixture of cash and about 328,000 shares of Diplomat stock. 

 

NORTH CHICAGO — Biopharmaceutical company AbbVie on Thursday announced its planned acquisition of Stemcentrx and its late-stage potential treatment for small cell lung cancer, Rova-T (rovalpituzumab tesirine). 

 

CONSHOHOCKEN, Pa. - The AmerisourceBergen Foundation and AmerisourceBergen associates on Thursday announced two donations totaling $32,000 to support rare disorder research. The donations were awarded to the Canadian Organization for Rare Disorders and the National Organization for Rare Disorders, two non-profit organizations devoted to identifying and treating rare disorders through patient services and education, advocacy and research programs.

 

BOSTON — Specialty prescribing platform ZappRx announced Wednesday that Lorrie Carr would be joining the company as its chief commercial officer. Most recently, Carr was Walgreens’ divisional VP enterprise specialty sales and product management. Carr will oversee ZappRx’s commercialization efforts as it launches and looks to expand its specialty prescribing and management platform. 

 

FLINT, Mich. — Diplomat Pharmacy announced Tuesday that Jennifer Hagerman had been promoted to be the company’s VP education and quality. In her new role, Hagerman will oversee the company’s employee and external professional education and training program, Diplomat University. This area also contains the company’s quality assurance department. 

 

SILVER SPRING, Md. — The Food and Drug Administration has approved Exelixis’ Cabometyx (cabozantinib) tablets, the company announced this week. Cabometyx is indicated to treat patients with advanced renal cell carcinoma who have previously received anti-angiogenic treatment. 

 

SILVER SPRING, Md. — The Food and Drug administration have approved AbbVie’s Viekira Pak for use without ribavirin to treat certain patients with hepatitis C.

 

The new indication for Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) will allow it to be used for patients with genotype 1b chronic hepatitis C and compensated cirrhosis.